290 related articles for article (PubMed ID: 17907502)
1. Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Agarwal MB
J Assoc Physicians India; 2007 Jul; 55():507-10. PubMed ID: 17907502
[TBL] [Abstract][Full Text] [Related]
2. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
3. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
4. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
5. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
6. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
7. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
8. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
9. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
10. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
11. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A
Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
[TBL] [Abstract][Full Text] [Related]
12. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
13. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
14. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
15. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
16. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
[TBL] [Abstract][Full Text] [Related]
17. An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.
Zhang SJ; Li JY
Chin Med J (Engl); 2008 Sep; 121(18):1838-42. PubMed ID: 19080367
[No Abstract] [Full Text] [Related]
18. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.
Plo I; Vainchenker W
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S329-39. PubMed ID: 19778861
[TBL] [Abstract][Full Text] [Related]
19. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
[TBL] [Abstract][Full Text] [Related]
20. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]